Microbix (MBX | MBXBF) Investor Webinar: FQ2 2026 Results and Key Growth Priorities

Microbix Biosystems management provides an update on the Company’s Q2 2026 results, highlighting the ongoing execution of its diagnostics business, continued cost discipline, and a strong balance sheet. While the quarter reflected some timing and market-related headwinds, the team discusses the steps being taken to rebuild revenue momentum and advance commercial opportunities across its product portfolio. The webinar also covers key growth priorities, including expanding QAPs opportunities with large clients and major test manufacturers, renewed order activity from China, and continued progress on Kinlytic as the Company works toward future regulatory submissions and market-building activities. The session concludes with a management Q&A focused on revenue timing, customer demand, China market dynamics, and the longer-term outlook for Microbix. Learn more about Microbix Biosystems: https://microbix.com/ Stay connected with Adelaide Capital: 📬 Sign up for updates: https://www.adcap.ca/subscribe 📅 Check out upcoming webinars: https://www.adcap.ca/weekly-events 🎥 Join live investor sessions and hear directly from CEOs: https://www.adcap.ca/ ⚠️ Disclaimer: This video/webinar is for informational purposes only. Adelaide Capital is not responsible for investment decisions made based on its content. Full disclaimer: https://www.adcap.ca/media-disclaimer #AdelaideCapital #InvestorRelations #InvestorUpdate #InvestorNews #News #CapitalMarkets #SmallCaps #MidCaps #Investing #Stocks #StockMarket